Journal article · 2026 · Open access

Artificial intelligence in drug discovery: current trend, challenges and future perspectives

Sharanjit Kaur, Tanvi Sawhney, Sanjiv Duggal

International Journal of Pharmaceutical Research and Development, 8(5), 207–211 · Published 1 May 2026 · DOI 10.33545/26646862.2026.v8.i5b.347

Free PDFView at the publisherCite this paper

In brief

“Artificial intelligence in drug discovery: current trend, challenges and future perspectives” is a 2026 journal article by Sharanjit Kaur and 2 co-authors, published in International Journal of Pharmaceutical Research and Development. OpenAlex counts 0 citations as of 15 November 2026. It is open access: the full text is free to read at International Journal of Pharmaceutical Research and Development.

Citations
0
Authors
3

Abstract

Artificial intelligence (AI) is transforming the field of drug discovery by improving the speed, efficiency, and accuracy of the development process. Conventional drug discovery is time-consuming, expensive, and associated with a high rate of clinical failure. AI-based approaches, including machine learning (ML), deep learning (DL), natural language processing (NLP), and reinforcement learning (RL), enable researchers to analyze large biological and chemical datasets, identify potential therapeutic targets, and design new molecules with desired properties. These technologies are widely applied in target identification, virtual screening, lead optimization, toxicity prediction, and clinical trial planning. AI also supports precision medicine by integrating genomic, proteomic, and clinical data to guide personalized treatment strategies. Several AI-designed drug candidates have already entered clinical evaluation, highlighting the practical impact of these methods. Despite these advances, important challenges remain, including limitations in data quality, model interpretability, reproducibility, regulatory acceptance, and ethical concerns such as privacy and algorithmic bias. Emerging developments in explainable AI, federated learning, multi-omics integration, and hybrid computational models are expected to further enhance the reliability and applicability of AI-driven drug discovery. This review summarizes current applications of AI in pharmaceutical research, discusses major challenges, and outlines future directions for the development of safer, faster, and more cost-effective therapeutics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kaur, S., Sawhney, T., & Duggal, S. (2026). Artificial intelligence in drug discovery: current trend, challenges and future perspectives. International Journal of Pharmaceutical Research and Development, 8(5), 207–211. https://doi.org/10.33545/26646862.2026.v8.i5b.347

MLA 9

Kaur, Sharanjit, et al. “Artificial intelligence in drug discovery: current trend, challenges and future perspectives.” International Journal of Pharmaceutical Research and Development, vol. 8, no. 5, 2026, pp. 207–211. https://doi.org/10.33545/26646862.2026.v8.i5b.347.

Chicago

Kaur, Sharanjit, Tanvi Sawhney, and Sanjiv Duggal. 2026. “Artificial intelligence in drug discovery: current trend, challenges and future perspectives.” International Journal of Pharmaceutical Research and Development 8 (5): 207–211. https://doi.org/10.33545/26646862.2026.v8.i5b.347.

Harvard

Kaur, S., Sawhney, T. and Duggal, S. (2026) ‘Artificial intelligence in drug discovery: current trend, challenges and future perspectives’, International Journal of Pharmaceutical Research and Development, 8(5), pp. 207–211. doi:10.33545/26646862.2026.v8.i5b.347.

IEEE

S. Kaur, T. Sawhney, and S. Duggal, “Artificial intelligence in drug discovery: current trend, challenges and future perspectives,” International Journal of Pharmaceutical Research and Development, vol. 8, no. 5, pp. 207–211, 2026, doi: 10.33545/26646862.2026.v8.i5b.347.

BibTeX

@article{kaur2026artificial,
  title     = {{Artificial intelligence in drug discovery: current trend, challenges and future perspectives}},
  author    = {Kaur, Sharanjit and Sawhney, Tanvi and Duggal, Sanjiv},
  journal   = {International Journal of Pharmaceutical Research and Development},
  year      = {2026},
  volume    = {8},
  number    = {5},
  pages     = {207--211},
  doi       = {10.33545/26646862.2026.v8.i5b.347},
  url       = {https://doi.org/10.33545/26646862.2026.v8.i5b.347}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence in drug discovery
  • machine learning
  • deep learning
  • natural language processing
  • reinforcement learning
  • target identification
  • virtual screening
  • lead optimization

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Kaur, S., Sawhney, T., & Duggal, S. (2026). Artificial intelligence in drug discovery: current trend, challenges and future perspectives. International Journal of Pharmaceutical Research and Development, 8(5), 207–211. https://doi.org/10.33545/26646862.2026.v8.i5b.347

How many times has this paper been cited?

0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at International Journal of Pharmaceutical Research and Development.

Who wrote this paper?

Sharanjit Kaur, Tanvi Sawhney, Sanjiv Duggal.

What is the DOI of this paper?

10.33545/26646862.2026.v8.i5b.347. The permanent link is https://doi.org/10.33545/26646862.2026.v8.i5b.347.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.